Balstilimab

Catalog No.: AT0096

Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody designed to selectively target and inhibit the programmed cell death protein 1 (PD-1). This interaction is intended to enhance the body's immune response against various cancers by blocking the PD-1 pathway, which is often exploited by tumors to evade immune detection.

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Grouped product items
Size	Price	Stock
1mg	$240.00	In stock
5mg	$720.00	In stock
10mg	$1,160.00	In stock
Bulk Size	Bulk Discount

Bulk Inquiry

Notify me when the price drops

Free Delivery on orders over $500

Research use only. We do not sell to patients.

Loading distributor info...

Adooq Products cited in reputable paper

Biological Activity

Description	Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody designed to selectively target and inhibit the programmed cell death protein 1 (PD-1). This interaction is intended to enhance the body's immune response against various cancers by blocking the PD-1 pathway, which is often exploited by tumors to evade immune detection.

Product Information

Catalog Num	AT0096
CAS Number	2148321-77-9
Isotype	Human IgG4 (S228P) kappa, Isotype Control
Species	Human
Synonyms	AGEN2034

Useful Calculator

This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

* Please check COA/MSDS for correct molecular weight.

Calculate the dilution required to prepare a stock solution.
This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Frequently Asked Questions

What are Biosimilar Antibodies?

Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research. Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.